Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors. SSTR-RADS could guide the imaging specialist in interpreting SSTR PET scans, facilitate communication with the referring clinician so that appropriate workup for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned peptide receptor radionuclide therapy.
Keywords: 68Ga-DOTATATE/-TOC; PET; PRRT; RADS; SSTR; neuroendocrine tumor; peptide receptor radionuclide therapy; somatostatin receptor.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.